Effects of iloprost (ZK 36374), a prostacyclin derivative, on platelet function after ischaemic exercise in patients with stable angina pectoris.
The effect of a chemically stable prostacyclin analogue (Iloprost) on platelet function was investigated in a controlled study in patients with angiographically confirmed stable angina pectoris after ischaemic exercise. In placebo experiments, ADP platelet aggregation was increased after exercise only when measured in whole blood and not in PRP. While plasma thromboxane B2 levels were unchanged, those of 6-keto PGF1 alpha were significantly although transiently increased after exercise. Iloprost displayed a potent antiaggregating activity in PRP and also reversed platelet hyperaggregation occurring in whole blood determinations after exercise. Plasma thromboxane B2 levels were significantly reduced but occasionally a rebound increase occurred 30 min. after end of the infusion. In contrast plasma level of 6-keto PGF1 alpha did not change after Iloprost and its recorded post-exercise increase was counteracted, thus suggesting a negative feed-back mechanism between Iloprost and natural prostacyclin. The data also suggest that degradation of the analogue is probably accomplished through pathways different from those of PGI2.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000368:Aged; D000787:Angina Pectoris / Q000097:blood*; D001792:Blood Platelets / Q000187:drug effects*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D003327:Coronary Disease / Q000097:blood; D011464:Epoprostenol / Q000494:pharmacology*; D006801:Humans; D016285:Iloprost; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D010974:Platelet Aggregation / Q000187:drug effects; D010979:Platelet Function Tests; D011897:Random Allocation; D013929:Thromboxane B2 / Q000097:blood
D002317:Cardiovascular Agents; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D016285:Iloprost